Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors

Tuesday, September 24, 2024

Dr. Reva Schneider

Read the Story Here

Related Posts

Discover more posts like this.

First-in-human Phase 1/2a Trial of a Macrocyclic ATR inhibitor (ATRN-119) in Patients with Advanced Solid Tumors.

Oct 2, 2024

Dr. Reva Schneider

First-in-human results of STX-478, a mutant-selective PI3Kα inhibitor, in advanced solid tumor patients

Sep 24, 2024

Dr. Douglas Orr

First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable Disease

Sep 24, 2024

Dr. Douglas Orr
See All Posts